(Q36196489)

12 August 2017

1 reference

title

Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout (English)

1 reference

12 August 2017

H Ralph Schumacher

1

1 reference

PubMed ID

16022578

12 August 2017

language of work or name

English

0 references

publication date

1 July 2005

1 reference

Expert Opinion on Investigational Drugs

12 August 2017

1 reference

12 August 2017

14

1 reference

12 August 2017

7

1 reference

12 August 2017

893-903

1 reference

How is gout managed in primary care? A review of current practice and proposed guidelines

12 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.893

Incidence and risk factors for gout in white men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.893

A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.893

Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.893

Metabolic syndrome and ischemic heart disease in gout.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.893

Treatment of acute gouty arthritis: one physician's approach and where this management stands relative to developments in the field

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.893

Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.893

A single-blind, randomized, controlled trial to assess the efficacy and tolerability of rofecoxib, diclofenac sodium, and meloxicam in patients with acute gouty arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.893

How well have diagnostic tests and therapies for gout been evaluated?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.893

Long-term remission from gout associated with fenofibrate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.893

Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.893

Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.893

Acute adverse reactions attributed to allopurinol in hospitalised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.893

Allopurinol-induced suppressor T cell dysfunction: a hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.893

Inhibition of purine nucleoside phosphorylase activity and of T-cell function with allopurinol-riboside

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.893

Letter: Allopurinol and bone-marrow depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.893

An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.893

Hypouricemic effect of allopurinol and the novel xanthine oxidase inhibitor TEI-6720 in chimpanzees.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.893

Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.893

Inhibition of human erythrocyte orotidylate decarboxylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.893

Effect of TEI-6720, a xanthine oxidase inhibitor, on the nucleoside transport in the lung cancer cell line A549.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.893

Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.893

Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.893

PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.893

Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.7.893

10.1517/13543784.14.7.893

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

16022578